Polysubstituted cyclopropanes were efficiently prepared with poly（ethylene glycol）（PEG） as soluble support. The reaction of PEG-supported pyridinium ylide with arylidenemalononitrile（R=CN） or ethyl arylidenecyan...Polysubstituted cyclopropanes were efficiently prepared with poly（ethylene glycol）（PEG） as soluble support. The reaction of PEG-supported pyridinium ylide with arylidenemalononitrile（R=CN） or ethyl arylidenecyanoa-cetate（R=COOEt） in the presence of triethylamine（TEA） afforded PEG-supported cyclopropanecarboxylates, which were cleaved by 1% KCN/EtOH to obtain polysubstituted cyclopropanes with exclusive trans-selectivity and good yields.展开更多
Background Although heart transplantation has become a standard therapy for end-stage heart disease, there are few published studies regarding the use of transplant organs from marginal donors. Here we describe the cl...Background Although heart transplantation has become a standard therapy for end-stage heart disease, there are few published studies regarding the use of transplant organs from marginal donors. Here we describe the clinical outcome we have obtained using marginal donor hearts.Methods We analyzed 21 cases of orthotropic heart transplantation for end-stage heart disease performed in our department between September 2008 and July 2010. Of these patients, six received hearts from marginal donors and the remainder received standard-donor hearts. The two groups were compared in terms of both mortality and the incidence of perioperative complications such as infection, acute rejection, and right heart insufficiency.Results The 1-year survival rate of both groups was 100%. Only one death was recorded in standard-donor group during follow-up. Patients who received marginal donor hearts （83%） experienced more early complications than did the standard-donor-heart group （13%）, but the mortality of the two groups was the same. The duration of post-ICU stay was greater in the marginal donor group than in the standard-donor group, （35.5±17.4） days and （21.7±2.6） days, respectively （P ＜0.05）.Conclusions The use of marginal donor hearts increases the number of patients who can receive and benefit from transplants. However, it may introduce an increased risk of early complications, thus care should be taken both in the choice of patients who will receive marginal donor hearts and in the perioperative treatment of those for whom the procedure is performed.展开更多
基金Supported by the National High Technology Research and Development Program of China(No.2009AA03Z420)the Natural Science Foundation of Hubei Province of China(Nos.2007ABA031,2008CDA078)
文摘Polysubstituted cyclopropanes were efficiently prepared with poly（ethylene glycol）（PEG） as soluble support. The reaction of PEG-supported pyridinium ylide with arylidenemalononitrile（R=CN） or ethyl arylidenecyanoa-cetate（R=COOEt） in the presence of triethylamine（TEA） afforded PEG-supported cyclopropanecarboxylates, which were cleaved by 1% KCN/EtOH to obtain polysubstituted cyclopropanes with exclusive trans-selectivity and good yields.
文摘Background Although heart transplantation has become a standard therapy for end-stage heart disease, there are few published studies regarding the use of transplant organs from marginal donors. Here we describe the clinical outcome we have obtained using marginal donor hearts.Methods We analyzed 21 cases of orthotropic heart transplantation for end-stage heart disease performed in our department between September 2008 and July 2010. Of these patients, six received hearts from marginal donors and the remainder received standard-donor hearts. The two groups were compared in terms of both mortality and the incidence of perioperative complications such as infection, acute rejection, and right heart insufficiency.Results The 1-year survival rate of both groups was 100%. Only one death was recorded in standard-donor group during follow-up. Patients who received marginal donor hearts （83%） experienced more early complications than did the standard-donor-heart group （13%）, but the mortality of the two groups was the same. The duration of post-ICU stay was greater in the marginal donor group than in the standard-donor group, （35.5±17.4） days and （21.7±2.6） days, respectively （P ＜0.05）.Conclusions The use of marginal donor hearts increases the number of patients who can receive and benefit from transplants. However, it may introduce an increased risk of early complications, thus care should be taken both in the choice of patients who will receive marginal donor hearts and in the perioperative treatment of those for whom the procedure is performed.
